Media coverage
18
Media coverage
Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet BioSpace Country/Territory United States Date 12/07/21 URL https://www.biospace.com/article/releases/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to-severely-active-ulcerative-colitis-at-nearly-three-years-in-long-term-extension-of-phase-3-trial/?s=95 Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet CompanyNewsHQ Country/Territory United Kingdom Date 10/07/21 URL https://www.companynewshq.com/company-news/pharmaceutical-company-news/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to-severely-active-ulcerative-colitis-at-nearly-three-years-in-long-ter/ Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Janssen Country/Territory United States Date 10/07/21 URL https://www.janssen.com/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Impact Financial News Country/Territory United Kingdom Date 10/07/21 Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Morningstar.com Country/Territory United States Date 9/07/21 URL https://www.morningstar.com/news/pr-newswire/20210709ph37202/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to-severely-active-ulcerative-colitis-at-nearly-three-years-in-long-term-extension-of-phase-3-trial Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Yahoo! Finance Country/Territory United States Date 9/07/21 URL https://finance.yahoo.com/news/stelara-ustekinumab-demonstrated-sustained-symptomatic-151000587.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet MarketScreener.com Country/Territory United States Date 9/07/21 URL https://www.marketscreener.com/news/latest/STELARA-ustekinumab-Demonstrated-Sustained-Symptomatic-and-Corticosteroid-Free-Remission-Rates-in--35828830/ Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet TickerTech.com Country/Territory United States Date 9/07/21 URL www.tickertech.com/cgi/?a=news&ticker=a&w=&story=202107202107091110PR_NEWS_USPR_____PH37202 Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet ProfitQuotes.com Country/Territory United States Date 9/07/21 URL www.profitquotes.com/cgi/?a=news&ticker=a&w=&story=202107202107091110PR_NEWS_USPR_____PH37202 Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Yahoo! News Country/Territory United States Date 9/07/21 URL https://www.yahoo.com/now/stelara-ustekinumab-demonstrated-sustained-symptomatic-151000587.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Yahoo! Finanzas Country/Territory United States Date 9/07/21 URL https://es-us.finanzas.yahoo.com/news/stelara-ustekinumab-demonstrated-sustained-symptomatic-151000587.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet WFMZ-TV Online Country/Territory United States Date 9/07/21 URL https://www.wfmz.com/news/pr_newswire/pr_newswire_business/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to/article_db81b906-ff57-5d27-84d0-dc203469b64a.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Phoenixville Phoenix Country/Territory United States Date 9/07/21 URL https://www.phoenixvillenews.com/news/state/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to/article_69d09947-6720-55c2-a4fe-c1edc61b130a.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Lansdale Reporter Country/Territory United States Date 9/07/21 URL https://www.thereporteronline.com/news/state/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to/article_4e63fbf3-7e7c-550a-9542-49596caeca7e.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Pottstown Mercury Country/Territory United States Date 9/07/21 URL https://www.pottsmerc.com/news/state/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to/article_966faac9-737f-507a-bb5d-188f0588fc60.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Norristown Times Herald Country/Territory United States Date 9/07/21 URL https://www.timesherald.com/news/state/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to/article_dbbdd7ca-1c47-5bc9-aa03-31fca54e1af2.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Bucks Local News Country/Territory United States Date 9/07/21 URL https://www.buckslocalnews.com/news/state/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to/article_5e4cf892-92f0-5cc6-ac64-73d25d91d534.html Persons Bruce E. Sands Title STELARA® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Rates in Adults with Moderately to Severely Active Ulcerative Colitis at Nearly Three Years in Long-Term Extension of Phase 3 Trial Media name/outlet Johnson & Johnson Country/Territory United States Date 9/07/21 URL https://www.jnj.com/stelara-ustekinumab-demonstrated-sustained-symptomatic-and-corticosteroid-free-remission-rates-in-adults-with-moderately-to-severely-active-ulcerative-colitis-at-nearly-three-years-in-long-term-extension-of-phase-3-trial Persons Bruce E. Sands